This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
overfunded
Active Needle Technology
130%
Raised
£195,480
Investors
223
Target
£150,000
Equity
4.96%
Pre-money valuation
£3,745,000

Active Needle’s award-winning, patent-pending technology has high-value applications in multiple medical and consumer areas. Its ultrasonic technology greatly enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others.

  • High value medical and consumer applications
  • Proprietory ultrasonic technology (patents filled)
  • The tattoo market in the USA alone was worth $1.5Bn in 2018
  • Highly experienced team

Idea

Image guided needles are widely used in medicine. However, the problem with needles is that they can be difficult to see and can bend away from their target. Active Needle solves this problem by greatly enhancing needle visibility and reducing off-target bending. Reducing bending and increasing visibility has the potential to reduce complications, save healthcare systems millions and increase treatment efficacy.

Ultrasonic needles has also been shown to reduce skin penetration forces. This effect can reduce skin trauma and pain. With ¼ of the UK and US population having at least 1 tattoo, a low pain tattooing system has obvious commercial advantages. The company has received an Innovate UK grant to develop and test the tattoo device.

Both medical and consumer devices are designed in a razor-razorblade configuration, and in our opinion, most of the value is in the needles. In medical applications, the superior product aims to displace current devices and uses pre-existing payment schemes. Tattoo devices will command a premium..

Needle biopsy and anaesthesia markets are worth $2bn with a CAGR of 7%. For tattoo, the US market is worth $1.6bn, with strong growth globally: 1/3 of 24-39 year olds in the UK and US have tattoos. Active Needle will used funds raised to complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Active Needle Technology pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Active Needle Technology has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.